齐拉西酮与氯氮平对90例精神分裂症患者疗效及体重的影响  

A comparative study on the efficacy and weight gain between Ziprasidone and Clozapine in the treatment of schizophrenia

作　　者：徐喜云 郭秋玲[1] 白常林 张衍军[1] 

机构地区：[1]山东省济宁市荣复军人医院,山东济宁272101

出　　处：《中国民康医学》2011年第11期1349-1351,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:探讨齐拉西酮与氯氮平对精神分裂症的疗效及对体重的影响。方法:对90例精神分裂症患者随机分组治疗,齐拉西酮组45例,氯氮平组45例,观察8周。两组于治疗前及治疗第2、4、8周末分别测定阳性与阴性症状量表(PANSS)、不良反应量表(TESS)、体重及体重指数(BMI),并与健康人对照。结果:齐拉西酮组各时点的PANSS总分及减分率与氯氮平组无显著性差异(P﹥0.05),氯氮平组不良反应较多,氯氮平组在治疗第48、周末的体重及体重指数均显著高于齐拉西酮组与健康对照组(P﹤0.05)。齐拉西酮组与健康对照组的体重及体重指数各时点比较无显著性差异(P﹥0.05)。结论:齐拉西酮治疗精神分裂症的疗效与氯氮平相当,不良反应少,对患者体重无显著影响。Objective：To compare the efficacy and weight gain of Ziprasidone and Clozapine in the treatment of schizophrenia.Methods：A total of 90 patients with schizophrenia were randomly divided into two groups,Ziprasidone group and Clozapine group.Body weight,Body Mass Index（BMI）,Positive and Negative Symptoms Scale（PANSS） and treatment and Emergent Symptoms Sccle（TESS） were used to measure efficacy and safety before treatment and at the end of 2 th、4 th、8 th week after treatment.Results： No significant differences were found between the two groups in total scores and reducing rates of PANSS in each period of treatmend（P﹥0.05）.While Ziprasidone group showed significantly more side effects（P﹤0.05）.Body weight and BMI showed significantly higher at the end of 4 th and 8 th week of treatment in the Clozapine group than in Ziprasidone group and healthy control（P〈0.05）.Body weight and BMI had no Significant differences between Ziprasidone group and healthy control（P〉0.05）.Conclusions： Quetiapine is aseffective as clozapine for the treatment of schizophrenia and has fewer side effects.It has no significant effect on body weight.

关 键 词：精神分裂症 齐拉西酮 氯氮平 疗效 体重 

分 类 号：R749.3[医药卫生—神经病学与精神病学]